Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi AppTec's STA Pharma to Expand Changzhou Site

publication date: Feb 3, 2017
SynTheAll (STA) Pharma, WuXi AppTec's small-molecule process development and manufacturing subsidiary, announced plans to expand its one-year-old Changzhou campus. In the short term, STA will raise its headcount to 300 scientists from 200 and increase reactor volume from 290 cubic meters to 490 cubic meters. Eventually, STA expects the site will be home to 500 scientists and offer 1,500 cubic meters of reactor volume. In 2014, WuXi sold 11% of STA to management and outside investors, listing the company on China's OTC exchange, NEEQ. The funding valued STA at $1.3 billion. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here